These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15755478)

  • 1. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
    Hallett PJ; Dunah AW; Ravenscroft P; Zhou S; Bezard E; Crossman AR; Brotchie JM; Standaert DG
    Neuropharmacology; 2005 Mar; 48(4):503-16. PubMed ID: 15755478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
    Dunah AW; Wang Y; Yasuda RP; Kameyama K; Huganir RL; Wolfe BB; Standaert DG
    Mol Pharmacol; 2000 Feb; 57(2):342-52. PubMed ID: 10648644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
    Fiorentini C; Rizzetti MC; Busi C; Bontempi S; Collo G; Spano P; Missale C
    Mol Pharmacol; 2006 Mar; 69(3):805-12. PubMed ID: 16365282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
    Silverdale MA; Crossman AR; Brotchie JM
    Exp Neurol; 2002 Mar; 174(1):21-8. PubMed ID: 11869030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease.
    Betarbet R; Poisik O; Sherer TB; Greenamyre JT
    Exp Neurol; 2004 May; 187(1):76-85. PubMed ID: 15081590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
    Dunah AW; Sirianni AC; Fienberg AA; Bastia E; Schwarzschild MA; Standaert DG
    Mol Pharmacol; 2004 Jan; 65(1):121-9. PubMed ID: 14722243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
    Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms.
    Blanchet PJ; Calon F; Morissette M; Hadj Tahar A; Bélanger N; Samadi P; Grondin R; Grégoire L; Meltzer L; Di Paolo T; Bédard PJ
    Parkinsonism Relat Disord; 2004 Jul; 10(5):297-304. PubMed ID: 15196509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B; Hoyer D; Grégoire L; Morissette M; Gasparini F; Gomez-Mancilla B; Di Paolo T
    Neuroscience; 2010 Jun; 167(4):1160-7. PubMed ID: 20303391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B; Belkhir S; Morissette M; Dridi M; Samadi P; Grégoire L; Meltzer LT; Di Paolo T
    J Mol Neurosci; 2009 Jun; 38(2):128-42. PubMed ID: 18704766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane.
    Dunah AW; Standaert DG
    J Neurosci; 2001 Aug; 21(15):5546-58. PubMed ID: 11466426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NR2A-containing NMDA receptors depress glutamatergic synaptic transmission and evoked-dopamine release in the mouse striatum.
    Schotanus SM; Chergui K
    J Neurochem; 2008 Aug; 106(4):1758-65. PubMed ID: 18540994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
    Hallett PJ; Standaert DG
    Pharmacol Ther; 2004 May; 102(2):155-74. PubMed ID: 15163596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.
    Huot P; Johnston TH; Winkelmolen L; Fox SH; Brotchie JM
    Neurobiol Aging; 2012 Jan; 33(1):194.e5-15. PubMed ID: 20561716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.